Menu
Patented technology that transforms key inflammatory messengers from agents of destruction to agents of repair
Enables you to alter patients’ disease progression and put them on the path to healing
Seamlessly integrates into your critical-care workflow
Critically ill patients in the throes of a cytokine storm are facing an alarming, urgent situation. That’s because this dangerous, dysregulated hyperinflammatory response can cause multiorgan damage and in severe cases, death.
SeaStar Medical is an innovator with groundbreaking solutions that give you the power to stop this serious threat before it can do irreparable harm to the patients you are fighting for.
Backed by rigorous clinical research and robust scientific evidence, our patented approach is designed to support your clinical end goals including reducing dialysis dependency, improving outcomes, and saving precious lives.
Hyperinflammation, or the cytokine storm, develops when the immune system responds too aggressively to injury or infection. Acute kidney injury, acute respiratory distress syndrome, COVID-19, and many other health issues can result in a dangerous cytokine storm. With SeaStar Medical’s novel, simple-to-use SCD cell-directed extracorporeal therapy, you can quickly rescue patients from a cytokine storm, regardless of how it was triggered, and restore reparative functionality to the body and potentially reverse injury.
The SCD is an investigational device and is not currently available for sale. Please check back for further updates on device availability in your region.
Image shown for illustration only and is subject to change.
A shorter treatment regimen to reach the desired effect may reduce dependency on dialysis and time in the ICU. This can help put patients on the road back to recovery sooner and free up resources more quickly.
SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
©SeaStar Medical 2023